Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation

被引:13
|
作者
Wang, Wanzhong [1 ]
Bergh, Anders [2 ]
Damber, Jan-Erik [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Dept Urol, Inst Clin Sci, SE-41345 Gothenburg, Sweden
[2] Umea Univ, Dept Med Biosci, Umea, Sweden
关键词
p53; immunohistochemistry; immunofluorescence; proliferative inflammatory atrophy; inflammation; TUMOR-SUPPRESSOR GENE; GSTP1 CPG ISLAND; NITRIC-OXIDE; POSTATROPHIC HYPERPLASIA; INCREASED EXPRESSION; BENIGN PROSTATE; LUNG-CANCER; CARCINOGENESIS; MUTATIONS; PROTEIN;
D O I
10.1111/j.1600-0463.2008.00006.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Proliferative inflammatory atrophy (PIA) of prostate has been proposed as a precursor lesion of prostate cancer. The aim of the current study was to evaluate the expression of p53 protein in PIA lesions and to investigate the relationship between p53 staining and Ki-67, glutathione S-transferase-p (GSTP1) and cyclooxygenase-2 (COX-2) immunohistochemical expression. The results revealed that p53 nuclear immunostaining appeared in PIA lesions in 2.1 +/- 3.4% (mean +/- SD) of the basal and 0.9 +/- 2.3% of the luminal epithelial cells. Both these values were significantly higher than those in normal-appearing acini (p<0.0001). Increased p53 expression in luminal cells was related to focal infiltration of polymorphonuclear leucocytes. A positive correlation between p53 expression and Ki-67 was found in COX-2-positive PIA lesions (r = 0.610, p<0.0001). Half of the p53-positive epithelial cells expressed diffuse GSTP1 immunostaining in the same lesions. The present study demonstrates an increased p53 expression in PIA lesions, and inflammation, especially acute inflammation, may play a role in the induction of p53 over-expression, particularly as cells in PIA lesions are known to have a reduced defence against DNA damage.
引用
收藏
页码:185 / 195
页数:11
相关论文
共 50 条
  • [1] Proliferative activity and p53 immunoreactivity in primary and recurrent pterygia
    Hemo, Y
    Chowers, I
    Pe'er, J
    Zamir, E
    Ilsar, M
    Frucht-Pery, J
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S334 - S334
  • [2] Involvement of Inflammation and Proliferative Inflammatory Atrophy in prostate cancer development
    Perletti, G.
    Vral, A.
    Montanari, E.
    Gazzano, G.
    Marras, E.
    Magri, V.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S20 - S20
  • [3] p16 Is upregulated in proliferative inflammatory atrophy of the prostate
    Faith, DA
    Han, S
    Lee, DK
    De Marzo, AM
    Jarrard, DF
    LABORATORY INVESTIGATION, 2005, 85 : 140A - 140A
  • [4] p16 is upregulated in proliferative inflammatory atrophy of the prostate
    Faith, DA
    Han, S
    Lee, DK
    De Marzo, AM
    Jarrard, DF
    MODERN PATHOLOGY, 2005, 18 : 140A - 140A
  • [5] p16 is upregulated in proliferative inflammatory atrophy of the prostate
    Faith, D
    Han, S
    Lee, DK
    Friedl, A
    Hicks, JL
    De Marzo, AM
    Jarrard, DF
    PROSTATE, 2005, 65 (01): : 73 - 82
  • [6] P53 IMMUNOREACTIVITY IN INFLAMMATORY AND NEOPLASTIC DISEASES OF THE UTERINE CERVIX
    BOSARI, S
    RONCALLI, M
    VIALE, G
    BOSSI, P
    COGGI, G
    JOURNAL OF PATHOLOGY, 1993, 169 (04): : 425 - 430
  • [7] Inflammation, prostatitis, proliferative inflammatory atrophy: 'Fertile ground' for prostate cancer development?
    Perletti, Gianpaolo
    Montanari, Emanuele
    Vral, Anne
    Gazzano, Giacomo
    Marras, Emanuela
    Mione, Sylvia
    Magri, Vittorio
    MOLECULAR MEDICINE REPORTS, 2010, 3 (01) : 3 - 12
  • [8] P16 upregulation characterizes proliferative inflammatory atrophy of the prostate
    Han, S
    Lee, DK
    Demarzo, AM
    Friedl, A
    Jarrard, DF
    JOURNAL OF UROLOGY, 2002, 167 (04): : 137 - 137
  • [9] DNA CONTENT, TUMOR PROLIFERATIVE ACTIVITY (TPA) AND P53 IMMUNOREACTIVITY ON THYMOMA (T)
    ZAVALAPOMPA, A
    RO, JY
    SANDOSLARTIQUE, A
    ELNAGGAR, A
    ORDONEZ, NG
    AYALA, AG
    LABORATORY INVESTIGATION, 1995, 72 (01) : A156 - A156
  • [10] Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients
    Stattin, P
    Damber, JE
    Modig, H
    Bergh, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (05): : 885 - 889